Table 4.

Risk of thyroid nodules, benign thyroid nodules, and thyroid cancer by serum PTH.

	Model 1, OR (95% CI)	P value	Model 2, OR (95% CI)	P value
Thyroid nodules (n = 105)
ln (PTH) (1/ln (pg/mL))	0.79 (0.62–1.00)	0.052	0.88 (0.65–1.20)	0.884
Women	2.39 (1.33–4.30)	0.004	2.13 (1.13–3.99)	0.019
Adjusted serum calcium (1/mmol/L)	–	–	0.83 (0.41–1.68)	0.609
Cr (1/μmol/L)	–	–	1.00 (0.99–1.01)	0.222
Age	–	–	1.02 (0.99–1.04)	0.102
Benign thyroid nodules (n = 79)
ln (PTH) (1/ln (pg/mL))	0.88 (0.68–1.15)	0.354	1.04 (0.75–1.44)	0.835
Women	2.31 (1.21–4.43)	0.011	1.98 (0.98–3.98)	0.056
Adjusted serum calcium (1/mmol/L)	–	–	0.76 (0.35–1.66)	0.490
Cr (1/μmol/L)	–	–	0.99 (0.98–1.00)	0.132
Age	–	–	1.03 (1.00–1.05)	0.038
Thyroid cancer (n = 26)
ln (PTH) (1/ln (pg/mL))	0.52 (0.32–0.84)	0.008	0.50 (0.26–0.93)	0.028
Women	2.66 (0.87–8.09)	0.086	2.69 (0.83–8.75)	0.100
Adjusted serum calcium (1/mmol/L)	–	–	1.25 (0.35–4.50)	0.734
Cr (1/μmol/L)	–	–	1.00 (0.99–1.02)	0.855
Age	–	–	1.00 (0.96–1.03)	0.834

Multinomial adjusted logistic regression analyses for 318 patients with PHPT. Patients with primary hyperparathyroidism without thyroid nodules were used as a reference group. Model 1 is adjusted for gender. Model 2 is further adjusted for age, creatinine (Cr), and albumin-adjusted serum calcium.

ln, natural logarithm; PTH, parathyroid hormone.